about
Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis—the first 24 hNon-alcoholic fatty liver disease: a practical approach to diagnosis and stagingImplementation of a 'care bundle' improves the management of patients admitted to hospital with decompensated cirrhosisAge as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.Republished: Non-alcoholic fatty liver disease: a practical approach to treatment.Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.Postoperative methicillin-resistant Staphylococcus aureus enteritis following hysterectomy: a case report and review of the literature.Improving testing for hepatitis B before treatment with rituximab.Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial.Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.Improving access to treatment for patients with chronic hepatitis C through outreach.Decompensated alcohol related liver disease: acute management.Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers.Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?Summary of the British Transplantation Society UK Guidelines for Hepatitis E and Solid Organ Transplantation.Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use.Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy.Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England.Non-alcoholic fatty liver disease: a practical approach to treatment.Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.Reply to "Liver failure in human immunodeficiency virus - Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy".Changing epidemiology of chronic liver disease among ethnic groups in the United States.Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis.Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey.Editorial: improving in-hospital management of decompensated cirrhosis by a 'care bundle' - hope, frustration and lessons to learn. Authors' reply.Editorial: progress towards a simple tool for screening for hepatic steatosis in the general population.Editorial: further evidence for the use of advanced magnetic resonance imaging techniques to monitor NAFLD.Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered.Management of decompensated cirrhosis.Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice.An alcoholic patient who continues to drink: case presentation.A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated CirrhosisIncreased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicineDistance to treatment as a factor for loss to follow up of hepatitis C patients in North East EnglandBarriers and Facilitators to Mediterranean Diet Adoption by Patients with Non-alcoholic Fatty Liver Disease in Northern EuropeLiver transplant listing for hepatitis C associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct acting antiviral therapyInvestigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosisAcute hepatitis C in a nursing home resident
P50
Q26770382-7C8A26D1-28D5-4C91-9C97-54564091E1ABQ27006131-08AE55A6-1897-490C-8132-8C0BB9788D26Q33625935-EB3282DA-05C8-4DC3-ACD1-D88FD62B101FQ33639969-E626240A-0E45-4280-899F-24579D5A8B1DQ34785862-D3C83912-61DC-419A-9116-1633446ABB1FQ35135556-185A8DF2-0A8E-4076-A9AE-D780373E7592Q35965687-E261DC2A-0667-46CE-9E82-940E577DB1FDQ36282022-DD67D139-83CA-43CB-B674-995DF1C4818FQ37229995-F6B4B33F-9A79-400F-B039-68D602A4473FQ37541501-46435760-C7AC-46BA-900B-D2378C388BEAQ38204970-07B9FD44-37AE-4591-861B-1D750884CCEDQ38609143-36B1032C-6A3A-403E-9A3A-A1A4EA8C2364Q38712377-B0871593-CD9B-4FF5-A24D-5D209A84B05CQ38787752-6EC6763A-7811-49AB-8025-EEF94E9A4A56Q38873401-0754713F-931E-49AA-9B74-925A7E7701A2Q40088071-2395F9C2-84A9-4993-B371-48571AEDA3DEQ41022298-736603CA-4155-483D-B16E-4233A3B2FEBDQ41706904-32A32425-1116-4341-A2BA-6337DD19BF9EQ41725283-20C0CE5C-3A9F-4BF5-858D-E6A15BAEE232Q42279465-1042E312-C7E5-41F4-9436-4572CB0E14E3Q42913256-E54BF7E5-F0C5-4452-BD82-F8BE8B102855Q42923153-DE846F8A-7F29-4B5E-A562-222DB1FBFFA9Q42986190-2DF89F75-D8E8-4A13-8256-4FB9EC3230CDQ43823425-3DF5F666-B6A1-49D4-B420-C0EBC1C3839AQ47114927-EFED87E8-3546-4897-A0AF-1065ACFE95B1Q47234787-201C68E5-887F-4286-B3DB-44F9B2775867Q47588479-3416E7E7-254F-450D-8D54-016FAB689714Q48291741-366F4BF1-804D-4BB5-B8E3-5B5114C4D600Q48334549-AB425532-B2BE-4EBF-8017-09A79140F576Q51823144-623C7528-93EC-4373-88E8-9DB4646D5CB4Q52560329-FE85034A-B57D-44B5-94BA-24700FD733C9Q53588768-8A35674C-6DBF-4FC2-9EDE-D4D2041B0988Q54995560-ADFD2F5A-30EA-419C-9C31-56987B2D712EQ57300686-3B303776-5F14-47DC-A479-1DB35F1948A7Q57469085-058A6562-F86D-4E4F-91AC-286F60DF027EQ57798246-4CE6E7B9-E179-4519-B617-D03906C120A9Q58582828-0C8ED544-4CB2-434F-8591-D3347E74C7C5Q58588820-6E0951CB-050C-43B7-8162-4235A94CE06DQ61895897-0F8F78CB-FE0C-4A61-8049-6DBC7F431078Q81406526-731F50A9-CBD3-44FF-8EF0-247B183B9334
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Stuart McPherson
@en
Stuart McPherson
@nl
type
label
Stuart McPherson
@en
Stuart McPherson
@nl
prefLabel
Stuart McPherson
@en
Stuart McPherson
@nl
P31
P496
0000-0002-5638-2453